logo

Biotech Daily Dose

Share

pharma-daily-071918_15mar19.jpg Today's Daily Dose brings you news about the positive progress of Atossa Genetics' Oral Endoxifen as a post-mastectomy treatment for breast cancer; BioLife Solutions' stellar fourth-quarter financial results; BioPharmX Corp's anticipated milestones in 2019; revised FDA decision date of Karyopharm's Selinexor; and clinical trial catalysts of SCYNEXIS.

tickers-march11.jpg The clinical trial results of a drug company can impact its stock price depending upon the outcome - and more so if it is a small-/mid-cap biopharma stock. A keen understanding of the target timeline of the clinical trials will help trade biotech stocks with some margin of safety around the catalyst events.

pharma-022717_06mar19.jpg Today's Daily Dose brings you news about Invitae's secondary offering; BIOLASE's fourth-quarter financial results; Celgene's regulatory catalyst in September; and Endologix's reverse stock split, and the resignation of Scott Gottlieb as FDA Commissioner.

phaseiiidata-march04.jpg Listed below are some of the companies that are expected to report their phase III clinical trial results *this month (if the companies stick to their timeline).

spark-feb25.jpg It's raining blockbuster mergers & acquisitions in the pharma sector today - with Roche entering into a definitive merger agreement to acquire Spark Therapeutics, and Ipsen agreeing to acquire Clementia Pharmaceuticals.

pharma-022618_21feb19.jpg Today's Daily Dose brings you news about Exact Sciences' better-than-expected Q4 financial results; Merck's acquisition of Immune Design; Nevro's lackluster revenue outlook; Opiant Pharma' s disappointing Bulimia Nervosa study results; and near-term catalyst of Zosano Pharma.

pharma-031518_21feb19.jpg Today's Daily Dose brings you news about Achieve Life Sciences' progress in ORCA-1 trial; Agios Pharma's near-term regulatory catalyst; new development related to ARCA biopharma's PRECISION-AF pivotal study; financial outlook of Genomic Health and NuVasive; near-term clinical trial catalyst of Sarepta; and partial clinical hold on Xencor's phase I acute myeloid leukemia trial.

Follow RTT